| Literature DB >> 34206631 |
K K DurgaRao Viswanadham1, Roland Böttger1, Lukas Hohenwarter1, Anne Nguyen1, Elham Rouhollahi1, Alexander Smith1, Yi-Hsuan Tsai2, Yuan-Yu Chang3, Christopher Llynard Ortiz2,4,5, Lee-Wei Yang2,6, Liliana Jimenez1, Siyuan Li1, Chan Hur1, Shyh-Dar Li1.
Abstract
Opioids account for 69,000 overdose deaths per annum worldwide and cause serious side effects. Safer analgesics are urgently needed. The endogenous opioid peptide Leu-Enkephalin (Leu-ENK) is ineffective when introduced peripherally due to poor stability and limited membrane permeability. We developed a focused library of Leu-ENK analogs containing small hydrophobic modifications. N-pivaloyl analog KK-103 showed the highest binding affinity to the delta opioid receptor (68% relative to Leu-ENK) and an extended plasma half-life of 37 h. In the murine hot-plate model, subcutaneous KK-103 showed 10-fold improved anticonception (142%MPE·h) compared to Leu-ENK (14%MPE·h). In the formalin model, KK-103 reduced the licking and biting time to ~50% relative to the vehicle group. KK-103 was shown to act through the opioid receptors in the central nervous system. In contrast to morphine, KK-103 was longer-lasting and did not induce breathing depression, physical dependence, and tolerance, showing potential as a safe and effective analgesic.Entities:
Keywords: analgesics; dependence; enkephalin; pain; respiratory suppression; tolerance
Year: 2021 PMID: 34206631 DOI: 10.3390/pharmaceutics13070927
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321